Pardes is a clinical-stage biopharmaceutical company created by and for this moment to solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to develop novel drugs while reimagining the patient journey to access these medicines.
07/18/2022 1:26 AMEDT
There are no SEC filings available.
Send us an investor-related question using the form below.